- Conditions
- Herpes Simplex Virus Keratitis
- Interventions
- oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily, oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily + topical corticosteroid eye drops
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 100 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 261
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Metabolic Syndrome, Vascular Injury, Ischemic Preconditioning, Endothelial Function (reactive Hyperemia), Endothelial Dysfunction
- Interventions
- Ischemic preconditioning, Intravenous lactate infusion, No ischemic preconditioning (control), Normal Saline Infusion (Placebo), Ischemic preconditioning and intravenous lactate
- Procedure · Drug · Combination Product
- Lead sponsor
- Gary Van Guilder
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Gunnison, Colorado
- Conditions
- Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
- Interventions
- anti-thymocyte globulin, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, tacrolimus, nonmyeloablative allogeneic HSCT
- Biological · Drug · Procedure
- Lead sponsor
- Northside Hospital, Inc.
- Other
- Eligibility
- Up to 75 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Macular Degeneration
- Interventions
- VEGF Trap
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 8
- States / cities
- Tuscon, Arizona • Loma Linda, California • Chicago, Illinois + 5 more
- Conditions
- Community-acquired Pneumonia, Influenza, COVID-19
- Interventions
- Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
- Drug · Other · Biological + 1 more
- Lead sponsor
- UMC Utrecht
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 11
- States / cities
- Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
- Conditions
- Drug Addiction, Employment
- Interventions
- Employment-based abstinence reinforcement
- Behavioral
- Lead sponsor
- Northern Michigan University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Marquette, Michigan
- Conditions
- Diabetes Mellitus, Non-Insulin-Dependent
- Interventions
- Glimepiride
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2002
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Nicotine Dependence
- Interventions
- Brief Motivational Intervention, Contingency Management, Non-Contingent Reinforcement
- Behavioral
- Lead sponsor
- Brown University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Pregnancy, Sexually Transmitted Diseases
- Interventions
- Interactive multimedia platform, Intervention arm counseling, Standard of care counseling
- Behavioral
- Lead sponsor
- Centers for Disease Control and Prevention
- Federal
- Eligibility
- 14 Years to 19 Years · Female only
- Enrollment
- 709 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Abuse Potential
- Interventions
- gabapentin 600 mg, gabapentin 1200 mg, gabapentin 600 mg and oxycodone HCl 20 mg, gabapentin 1200 mg and oxycodone HCl 20 mg, oxycodone HCl 20 mg, placebo
- Drug
- Lead sponsor
- Viatris Specialty LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Marlton, New Jersey
- Conditions
- Bipolar Disorder, Schizo Affective Disorder
- Interventions
- High-Definition Transcranial Electrical-Current Stimulation, High-Definition Transcranial Alternate-Current Stimulation, High-Definition Personalized Beta-Gamma Electrical Stimulation
- Device
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Moderate to Severe Chronic Pain
- Interventions
- NKTR-181, Oxycodone IR
- Drug
- Lead sponsor
- Nektar Therapeutics
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Opiate Addiction
- Interventions
- Cannabidiol 400, Cannabidiol 800, Control
- Drug
- Lead sponsor
- Hurd,Yasmin, Ph.D.
- Individual
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Healthy
- Interventions
- ALKS 5461, Buprenorphine, Placebo
- Drug
- Lead sponsor
- Alkermes, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- HIV-1-infection
- Interventions
- GS-3242 Tablet, GS-3242 Injection, Lenacapavir Tablet, Lenacapavir Injection, B/F/TAF
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 30
- States / cities
- Beverly Hills, California • San Francisco, California • DeLand, Florida + 25 more
- Conditions
- Type 2 Diabetes
- Interventions
- Mulberry Leaf Extract, Placebo
- Drug
- Lead sponsor
- University of Mississippi Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Jackson, Mississippi
- Conditions
- Opioid Abuse
- Interventions
- 40/0mg taken first, 80/0mg taken first, 40/240mg taken first, 80/480mg taken first, 0/0mg taken first
- Drug
- Lead sponsor
- Acura Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Co-Occurring Alcohol and Drug Misuse
- Interventions
- CM for Alcohol, CM for drugs, CM for both substances, Non-Contingent group
- Behavioral
- Lead sponsor
- Washington State University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Spokane, Washington
- Conditions
- Latent Tuberculosis
- Interventions
- Usual Care, Video Directly Observed Therapy alone, Video Directly Observed Therapy plus Financial Incentives
- Behavioral
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 399 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Anxiety, Distress, Emotional, Effects of Vibration, Healthy
- Interventions
- Neuvana 2.0 Transcutaneous Auricular Vagal Nerve Stimulation (TaVNS), Waitlist Control, Healthy Controls: Substudy Group III, Distressed Workers: Subgroup II
- Other
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Human Immunodeficiency Virus, Medication Adherence
- Interventions
- Medication adherence and financial incentives
- Behavioral
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Major Depressive Disorder, Treatment Resistant Depression
- Interventions
- Nitrous oxide gas for inhalation, Placebo
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- HIV Prevention, Sexually Transmitted Infections (STI), Preexposure Prophylaxis (PrEP), Incarceration, Hepatitis C Virus (HCV), Substance Use Disorder (SUD)
- Interventions
- Mobile Enhanced Prevention Support (MEPS), Control
- Behavioral · Other
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years to 59 Years · Male only
- Enrollment
- 318 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2029
- U.S. locations
- 3
- States / cities
- Oakland, California • Riverside, California
- Conditions
- Diabetes Mellitus, Type 2, Diabetes Mellitus, Adult-Onset, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Noninsulin Dependent, Diabetes Mellitus, Type II
- Interventions
- Diabetes Knowledge/Information, Motivation/Behavioral Skills, Combined Intervention, Usual Care
- Behavioral
- Lead sponsor
- State University of New York at Buffalo
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 256 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina